肝素结合表皮生长因子在卵巢癌中的研究进展

摘要

肝素结合表皮生长因子(HB-EGF)是表皮生长因子家族成员之一,可通过激活表皮生长因子受体发挥生物学效应.近来研究表明,HB-EGF在卵巢癌中高水平表达并在肿瘤的发生发展中起重要作用,因此成为极具潜力的卵巢癌治疗靶点.系统描述HB-EGF的特性及其特异性抑制剂白喉毒素突变体(CRM197)的研究现状,并讨论CRM1197分别和膜型基质金属蛋白酶(MTl-MMP)抑制剂、去整合素-金属蛋白酶(ADAM)抑制剂及紫杉醇联合治疗卵巢癌的发展潜力.%Heparin binding-epidermal growth factor-like growth factor (HB-EGF) ,a member of the EGF family of growth factors,exerts its diverse biological activities through activation of the EGFR. Recently studies revealed HB-EGF expression was significantly elevated in ovarian cancer and it played a key role in the development of tumor,so HB-EGF was considered as a potential target for ovarian cancer therapy. The features of HB-EGF and the research progress of HB-EGF specific inhibitor CRM197 in therapy of ovarian cancer will be reviewed. We will also discuss the future direction for the development of therapeutic strategies targeting CRM197 and MTI-MMP inhibitor, AD AMs inhibitor, paclitaxel respectively.